Nano-X Imaging Ltd. (NNOX)
| Market Cap | 120.74M -58.0% |
| Revenue (ttm) | 13.02M +15.4% |
| Net Income | -75.02M |
| EPS | -1.16 |
| Shares Out | 69.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,479,350 |
| Open | 1.790 |
| Previous Close | 1.715 |
| Day's Range | 1.730 - 1.870 |
| 52-Week Range | 1.700 - 5.860 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+188.18%) |
| Earnings Date | Apr 20, 2026 |
About NNOX
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. The company’s solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source; and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to ... [Read more]
Financial Performance
In 2025, Nano-X Imaging's revenue was $13.02 million, an increase of 15.40% compared to the previous year's $11.28 million. Losses were -$75.02 million, 40.2% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NNOX stock is "Strong Buy" and the 12-month stock price target is $5.0.
News
NNOX Investors Have Opportunity to Join Nano-X Imaging Ltd. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nano-X Imaging L...
Growth Deal Meets Restructuring As Nano-X Eyes Margin Improvement
NANO-X IMAGING LTD (NASDAQ:NNOX) shares are up down on Wednesday as the company has entered into a strategic commercial agreement with Howard Technology Solutions.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Nano-X Imaging Earnings Call Transcript: Q4 2025
Q4 2025 saw expanded commercial agreements, a strategic acquisition, and a major manufacturing shift, driving a 23% revenue increase year-over-year. The company targets $35M revenue for 2026, with most growth expected in the second half as deployments ramp up.
Nanox.ARC X Digital Advanced 3D imaging built for access and powered by innovation Wins 2026 Red Dot Award for Product Design
International Red Dot Jury recognizes Nanox.ARC X for design excellence that brings advanced 3D tomosynthesis imaging into a wider range of clinical settings
Nanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas
Fourth distribution agreement of 2026 strengthens Nanox's U.S. commercial momentum PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (NASDAQ NNOX), a leader in innovative me...
Nanox to Report Fourth Quarter 2025 Financial Results on April 20, 2026
PETACH TIKVA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will rep...
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
New regional partnership strengthens Nanox 's presence and service support across outpatient imaging settings in Colorado , Wyoming and the western parts of Kansas and Nebraska
Nano-X Imaging Transcript: Investor Summit Virtual Conference
The presentation highlighted the company's FDA- and CE-cleared 3D imaging systems, innovative cold cathode technology, and expanding AI/software division. Commercialization is advancing in the U.S. and Europe, with flexible business models and strong operator margins.
Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast
Agreement with Imperial Imaging strengthens Nanox's commercial rollout across the orthopedic-rich segment in six U.S. Southeast states.
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd....
Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
PETACH TIKVA, Israel, Feb. 17, 2026 - NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will showcase its Nanox.ARC...
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US
Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina
Collaboration with Adriamed drives commercial expansion and strengthens Nanox's regional leadership Engagement supports continued growth across multiple European markets, following recent collaboratio...
Nano-X Imaging Transcript: Sidoti's Year End Virtual Investor Conference
Nanox.ARC X, a mobile 3D imaging system, and advanced AI tools received strong interest at RSNA and are now commercially deployed in the U.S. and EU. Financially, recent capital raises support expansion, with a focus on profitability and broadening clinical adoption.
Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System
Althea France, part of one of Europe's largest independent medical technology services provider s , to distribute CE-marked Nanox.ARC system across French healthcare sector
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
Nanox's HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated
Nanox Announces $15 Million Registered Direct Offering of Common Stock
PETACH TIKVA, Israel, Nov. 23, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has enter...
Nano-X Imaging Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue growth to $3.4M and a net loss of $13.7M, with strong teleradiology margins and global expansion. The VasoHealthcare IT acquisition was completed, supporting AI growth and a $35M revenue target for 2026, with break-even expected in 2027.
Vaso Corporation Announces Divestiture of Subsidiary
Vaso Corporation 137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact: Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorpora...
Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions
PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties ...
Nanox to Launch FDA-Cleared Nanox.ARC X and Present development of new AI innovations at RSNA 2025 Annual Meeting
Live demonstrations of Nanox.ARC X to be featured at RSNA booth ( 3914, South Hall Level 3) every 30 minutes Innovation Theater p resentation to highlight development of pulmonary nodule AI solution, ...
Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging
Collaboration spans workers' compensation, nursing homes, and outpatient clinics PETACH TIKVA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), a...
Nano-X Imaging Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue growth to $3.0M and a GAAP net loss of $14.7M, with over 20 imaging systems actively scanning patients and a target of 100 installations by year-end. Expansion in the U.S. and Europe, new AI collaborations, and a scalable manufacturing agreement position the company for accelerated growth in the second half of 2025.
Nanox to Report Second Quarter 2025 Financial Results on August 12, 2025
PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will repo...